T

hree months ago, Effendi Ortiz-Toro resigned from Shire Pharmaceuticals (SHPG), where he worked as sales director for the Midwest region, and took a job with Ultragenyx (RARE), which also sells rare-disease drugs. A few weeks later, three regional business managers followed him out the door and also joined Ultragenyx, a scenario that Shire alleges involved stealing confidential information.

In a lawsuit filed earlier this month, Shire claimed its former employees surreptitiously conspired to take valuable lists of doctors who specialize in treating rare disorders. As a result, Shire argued, Ultragenyx quickly gained a competitive edge and Shire asked a federal court to issue a restraining order to prevent Ultragenyx from marketing a newly approved medicine for treating a rare disease called Sly syndrome.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.